Emergent BioSolutions Faces Investigation Over Guidance Cuts
Emergent BioSolutions (EBS) is under investigation by Levi & Korsinsky, LLP, following significant reductions in its FY2026 revenue guidance. The company's stock has seen a sharp decline as investors assess the impact of these changes.
- Investors who purchased Emergent BioSolutions stock and sustained losses may have their claims evaluated concerning the pending securities law investigation. - Levi & Korsinsky, is investigating potential securities law violations related to Emergent BioSolutions' guidance reductions.